Although E-cadherin has been documented as a target of miR-9 in breast cancer [12], we further demonstrated that miR-9 directly targeted the 3′-UTR of E-Cadherin and activated the β-catenin signaling pathway in ESCC. Here, CDH1 is linked to breast carcinoma.